Skip to main content
. Author manuscript; available in PMC: 2015 Sep 9.
Published in final edited form as: Expert Opin Emerg Drugs. 2009 Sep;14(3):505–521. doi: 10.1517/14728210903146882

Table 1.

Existing treatments.

Treatment Main probable
mechanism(s) of action
Available
formulations
Indication Side effects Pros Cons
Aminosalycilates PPAR-γ agonism
Inhibition of arachidonic
acid metabolism
Inhibition of lymphocytes
proliferation
Oral and topical Induction and
maintenance of
remission
Hypersensitivity reactions
Interstitial nephritis
Acute pancreatitis
Blood disorders
Low incidence of side effects
Availability of many different
formulation for different
disease localization
Not suitable for severe
disease
Steroids Inhibition of NF-κB
activation
Oral, topical and
parenteral
Induction of remission Hyperglicemia
Hypertension
Osteoporosis
Cataracts
Glaucoma
Psycosis
Skin fragility
Malar fat pad increase
Visceral and truncal
fat deposition
Adrenal insufficiency
Increased infection
Good efficacy
Availability of many different
formulation for different
disease localization
and severity
High rate of side effects
Not suitable for
maintenance treatment
Low bioavailability
steroids
Inhibition of NF-κB
activation
Oral and topical Induction of remission Theoretically the same
as steroids
Low incidence of side effects
Availability of different
formulation for different
disease localization
Not suitable for severe
disease
Azathioprine
6-Mercaptpurine
Inhibition of leukocyte
proliferation
Induction of
lymphocyte apoptosis
Oral Maintenance of
remission
Leukopenia
Hepatitis
Pancreatitis
Hypersensitivity
Increased risk of
lymphoma (?)
Usually well tolerated Delayed therapeutic effect
Not suitable in a subset
of patients because of
intolerance/side effects
Cyclosporine Inhibition of calcineurin Oral and
parenteral
Induction and
maintenance of
remission
Hypertension
Nephropaty
Potassium retention
Gengival hyperplasia
Increased infections
Fast therapeutic effect
Suitable for induction,
much less for maintenance
of remission
High incidence of side
effects
Infliximab Circulating and
membrane-bound
TNF-α blockade
Apoptosis of TNF-α
producing cells
Parenteral Induction of remission
Maintenance of
remission (?)
Allergic reactions
Increased risk of
serious infection
Heart failure in
cardiopathic patients
Good efficacy
Fast therapeutic effect
Expensive
Unknown long-term
effects
Leukocytoapheresys Physical removal of
activated leukocytes
Induction of immune
tolerance
Not applicable Induction of remission Few and minor Safe Data not clear regarding
efficacy